MedTrace Logo

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

NCT03894124 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

Study to assess the pharmacokinetics of plasma doravirine once daily over 72 hours following drug intake cessation at steady-state in healthy volunteers

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Doravirine

Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Imperial College London

    collaborator OTHER

  • University of Liverpool

    collaborator OTHER

  • Chelsea and Westminster NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Marta Boffito · Chelsea and Westminster NHS Foundation Trust

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-12
Primary Completion
2019-07-25
Completion
2019-08-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03894124 on ClinicalTrials.gov